Ablynx raises $40M for R&D work

Belgium's Ablynx has raised about $40 million from a private placement of new shares. The fundraising provides the biotech additional cash to pursue the development of ALX-0061, go after new deals and advance its preclinical work. Just days ago Ablynx said it had struck a collaboration with Spirogen on novel toxin-nanobody drug conjugates in cancer, the latest in a string of pacts. Release


Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.